Abstract
Peripheral T lymphocytes are a target of choice for many gene therapeutic strategies. Retrovirus-mediated transduction allows genomic integration and long-term expression of transgenes in target cells. Over many years, low transduction efficiency into primary T lymphocytes has limited clinical application of existing protocols. Recently, gene transfer rates > 50% have been achieved facilitating clinical studies. More attention is thus being focused on the ability of gene-modified cells to carry out innate as well as conferred functions in vivo and the influence of culture conditions, retroviral vector and host response thereon.
Current Gene Therapy
Title: T Lymphocytes as Targets of Gene Transfer with Moloney-Type Retroviral Vectors
Volume: 1 Issue: 4
Author(s): F. A. Ayuk, A. R. Zander and B. Fehse
Affiliation:
Abstract: Peripheral T lymphocytes are a target of choice for many gene therapeutic strategies. Retrovirus-mediated transduction allows genomic integration and long-term expression of transgenes in target cells. Over many years, low transduction efficiency into primary T lymphocytes has limited clinical application of existing protocols. Recently, gene transfer rates > 50% have been achieved facilitating clinical studies. More attention is thus being focused on the ability of gene-modified cells to carry out innate as well as conferred functions in vivo and the influence of culture conditions, retroviral vector and host response thereon.
Export Options
About this article
Cite this article as:
Ayuk A. F., Zander R. A. and Fehse B., T Lymphocytes as Targets of Gene Transfer with Moloney-Type Retroviral Vectors, Current Gene Therapy 2001; 1 (4) . https://dx.doi.org/10.2174/1566523013348274
| DOI https://dx.doi.org/10.2174/1566523013348274 |
Print ISSN 1566-5232 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Epigenetic Mechanisms in Human Diseases and Gene Therapy
Epigenetic mechanisms including DNA methylation, histone post-translational modifications, non-coding RNAs and chromatin remodeling play crucial roles in gene expression. Aberrant epigenetic changes are often correlated with human diseases and metabolic disorders. Since gene expression can be activated/inactivated by reversible epigenetic mechanisms, increasing studies have been focused on epigenetic regulation in ...read more
Gene- and Cell-Based Therapeutics in Prostate Cancer: Emerging Opportunities and Challenges
Prostate cancer is the second most frequently diagnosed cancer in men worldwide and remains a leading cause of cancer mortality. While advances in androgen receptor–targeted therapies, radioligand treatment, and immunotherapy have improved outcomes, resistance and disease progression continue to present major challenges. Recent breakthroughs in gene and cell therapies — ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The Now and Future of Gene Transfer Technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Unorthodox Inhibitors of HIV Protease: Looking Beyond Active-site-directed Peptidomimetics
Current Pharmaceutical Design Transition Metal Based Anticancer Drugs
Current Topics in Medicinal Chemistry Molecular Imaging Probe Development Using Microfluidics
Current Organic Synthesis Antibodies and their Multivalent Constructs for Cancer Therapy
Protein & Peptide Letters New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2
Current Medicinal Chemistry - Anti-Cancer Agents Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
Current Clinical Pharmacology Modeling Anti-HIV Compounds: The Role of Analogue-Based Approaches
Current Computer-Aided Drug Design Regenerative Medicine and Nanotechnology Approaches against Cardiovascular Diseases: Recent Advances and Future Prospective
Current Stem Cell Research & Therapy Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets AIDS-Related Kaposis Sarcoma: State of the Art and Therapeutic Strategies
Current HIV Research Ex Vivo Gene Therapy and Vision
Current Gene Therapy Multimodality Imaging of RNA Interference
Current Medicinal Chemistry Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols
Current Cancer Drug Targets Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel
Anti-Cancer Agents in Medicinal Chemistry Pathogenic Roles of m6A Modification in Viral Infection and Virus-driven Carcinogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Mesenchymal Stromal Cells in Rheumatoid Arthritis: Biological Properties and Clinical Applications
Current Stem Cell Research & Therapy Monofunctional Platinum (PtII) Compounds – Shifting the Paradigm in Designing New Pt-based Anticancer Agents
Current Medicinal Chemistry Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques
Current Bioactive Compounds Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Novel Strategies to Discover Effective Drug Targets in Metabolic and Immune Therapy for Glioblastoma
Current Cancer Drug Targets





